Cell line · CVCL_0178
Papers88
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 88
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| VCP-Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of HOX/PBX Dimers as a Potential Therapeutic Strategy in Breast Cancer Subtypes Including Triple Negative Breast Cancer. | Curr Issues Mol Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ENO2 sustains cancer stemness and metastatic competence through a phosphoenolpyruvate-dependent metabolic axis in triple-negative breast cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of novel circular RNAs of the apoptosis-related BAX gene in breast cancer, by combining nanopore and next-generation sequencing. | Mol Genet Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| COMP-PMEPA1 axis promotes epithelial-to-mesenchymal transition in breast cancer cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LDAcoop: Integrating non-linear population dynamics into the analysis of clonogenic growth in vitro. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Notch1 regulates Orai1 and Orai3 expression in breast cancer cells. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer. | Breast Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrative miRNOMe profiling reveals the miR-195-5p-CHEK1 axis and its impact on luminal breast cancer outcomes. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0178/papers